Clovis Oncology, Inc.
CLVSUnited States
30 filed reports · 475 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
30 reports · Jun 2015 to Sep 2022Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 23 | 3,733 | Jun 2015 to Sep 2022 |
| Annual · 10-KSEC EDGAR | 7 | 3,757 | Dec 2015 to Dec 2021 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2022 Q3 | 10-Q | 2022-09-30 | 2022-11-09 | 409 | Open |
| FY2022 Q2 | 10-Q | 2022-06-30 | 2022-08-08 | 251 | Open |
| FY2022 Q1 | 10-Q | 2022-03-31 | 2022-05-05 | 259 | Open |
| FY2021 | 10-K | 2021-12-31 | 2022-02-24 | 956 | Open |
| FY2021 Q3 | 10-Q | 2021-09-30 | 2021-11-03 | 170 | Open |
| FY2021 Q2 | 10-Q | 2021-06-30 | 2021-08-04 | 152 | Open |
| FY2021 Q1 | 10-Q | 2021-03-31 | 2021-05-05 | 182 | Open |
| FY2020 | 10-K | 2020-12-31 | 2021-02-25 | 538 | Open |
| FY2020 Q3 | 10-Q | 2020-09-30 | 2020-11-05 | 180 | Open |
| FY2020 Q2 | 10-Q | 2020-06-30 | 2020-08-07 | 154 | Open |
| FY2020 Q1 | 10-Q | 2020-03-31 | 2020-05-06 | 165 | Open |
| FY2019 | 10-K | 2019-12-31 | 2020-02-26 | 495 | Open |
Financial data
475 concepts · 7,490 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial463 concepts · 7,189 facts · Jun 2013 to Nov 2022
- Allocated share based compensation expense44 · Dec 2013 to Sep 2022
- Cash and cash equivalents at carrying value44 · Dec 2013 to Sep 2022
- Comprehensive income net of tax44 · Dec 2013 to Sep 2022
- Employee service share based compensation tax benefit from compensation expense44 · Dec 2013 to Sep 2022
- Foreign currency transaction gain loss before tax44 · Dec 2013 to Sep 2022
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest44 · Dec 2013 to Sep 2022
- Income tax expense benefit44 · Dec 2013 to Sep 2022
- Net income loss44 · Dec 2013 to Sep 2022
- Nonoperating income expense44 · Dec 2013 to Sep 2022
- Operating income loss44 · Dec 2013 to Sep 2022
- Other nonoperating income expense44 · Dec 2013 to Sep 2022
- Research and development expense excluding acquired in process cost44 · Dec 2013 to Sep 2022
- Depreciation depletion and amortization42 · Dec 2013 to Sep 2022
- Increase decrease in accounts payable42 · Dec 2013 to Sep 2022
- Increase decrease in other accrued liabilities42 · Dec 2013 to Sep 2022
- Increase decrease in other operating assets42 · Dec 2013 to Sep 2022
- Increase Decrease In Prepaid And Accrued Research And Development Expenses42 · Dec 2013 to Sep 2022
- Payments to acquire property plant and equipment42 · Dec 2013 to Sep 2022
- Share based compensation42 · Dec 2013 to Sep 2022
- Accumulated other comprehensive income loss net of tax41 · Dec 2013 to Sep 2022
- Amortization of financing costs41 · Sep 2014 to Sep 2022
- Interest expense debt41 · Sep 2014 to Sep 2022
- Interest expense debt excluding amortization41 · Sep 2014 to Sep 2022
- Stockholders equity (US GAAP)41 · Dec 2013 to Sep 2022
Segment10 concepts · 239 facts · Dec 2018 to Sep 2022
- Cost of goods and services sold (US GAAP)63 · Dec 2018 to Sep 2022
- Operating income loss30 · Dec 2018 to Sep 2022
- Research and development expense excluding acquired in process cost30 · Dec 2018 to Sep 2022
- Selling general and administrative expense30 · Dec 2018 to Sep 2022
- Revenue29 · Dec 2018 to Sep 2022
- Costs and expenses24 · Dec 2019 to Sep 2022
- Operating expenses (US GAAP)14 · Dec 2018 to Jun 2021
- Other cost and expense operating14 · Dec 2019 to Sep 2022
- Acquired in-process research and development4 · Dec 2019 to Dec 2021
- Research and development in process1 · Dec 2019
Product2 concepts · 62 facts · Dec 2016 to Sep 2022
- Cost of goods and services sold (US GAAP)59 · Dec 2016 to Sep 2022
- Revenue3 · Dec 2018 to Dec 2020
Segments
301 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments2 members · 239 facts
- U.S.130 · Dec 2018 to Sep 2022
- ex U.S.109 · Dec 2018 to Sep 2022
Product or servicesrt:ProductOrServiceAxis2 members · 60 facts
- Product32 · Dec 2016 to Sep 2022
- Intangible assets amortization28 · Mar 2017 to Sep 2022
Product or serviceus-gaap:ProductOrServiceAxis1 member · 2 facts
- Product2 · Mar 2017 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Clovis Oncology, Inc. (CLVS) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.